Raia Drogasil S.A. (OTCMKTS:RADLY – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $3.9660, but opened at $3.7930. Raia Drogasil shares last traded at $3.7930, with a volume of 1,173,000 shares trading hands.
Analyst Upgrades and Downgrades
Separately, Zacks Research raised shares of Raia Drogasil to a “hold” rating in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.
View Our Latest Research Report on RADLY
Raia Drogasil Stock Performance
Raia Drogasil (OTCMKTS:RADLY – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.05 EPS for the quarter, hitting analysts’ consensus estimates of $0.05. The firm had revenue of $2.17 billion during the quarter, compared to analyst estimates of $2.32 billion. As a group, equities research analysts anticipate that Raia Drogasil S.A. will post 0.16 earnings per share for the current fiscal year.
Raia Drogasil Company Profile
Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.
The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.
Featured Articles
- Five stocks we like better than Raia Drogasil
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.
